Mar 31, 2017 8:05 am EDT Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
Mar 8, 2017 8:15 am EST Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
Mar 7, 2017 7:45 am EST Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
Mar 3, 2017 7:44 am EST Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
Feb 21, 2017 7:48 am EST Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
Feb 17, 2017 7:45 am EST Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
Feb 7, 2017 7:45 am EST Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017
Feb 1, 2017 7:43 am EST Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A
